Berobenatide vs Semaglutide (DWRX5003)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1 receptor · full Obesity pipeline

Berobenatide

Developed by Pfizer

Phase 3 in Obesitypeptide
Partial signal

NCT06712836 · Phase 2 · completed

The study randomized 239 participants to MET097 or placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical outcome of body-weight change at Week 28. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: January 2027 · NCT07508241 (registry estimate)

Reported efficacy

Percent change from baseline in body weight at Week 28 (Baseline (Week 0) through Week 28 (Day 197)): Percent change in body weight at week 28 (Part A): berobenatide 0.4, 0.6, 0.9 and 1.2 mg weekly -6.41%, -8.36%, -11.29% and -12.45% vs placebo +1.67%; placebo-adjusted -8.09% to -14.13%, all p<0.0001 (CT.gov posted results). (met)

Result source: NCT06712836

Semaglutide (DWRX5003)

Developed by Daewoong Pharmaceutical

Phase 1 in Obesitypeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBerobenatideSemaglutide (DWRX5003)
Body weight, % change—Trial running · NCT07311850—Not reported
Weight loss of 5% or more—Trial running · NCT07311850—Not reported
Weight loss of 10% or more—Trial running · NCT07311850—Not reported
Waist circumference, change (cm)—Trial running · NCT07311850—Not reported

Body weight, % change

Berobenatide
—Trial running · NCT07311850
Semaglutide (DWRX5003)
—Not reported

Weight loss of 5% or more

Berobenatide
—Trial running · NCT07311850
Semaglutide (DWRX5003)
—Not reported

Weight loss of 10% or more

Berobenatide
—Trial running · NCT07311850
Semaglutide (DWRX5003)
—Not reported

Waist circumference, change (cm)

Berobenatide
—Trial running · NCT07311850
Semaglutide (DWRX5003)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Semaglutide (DWRX5003): no structured comparison results are available for Obesity.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Berobenatide
Percent change in body weight at week 28 (Part A): berobenatide 0.4, 0.6, 0.9 and 1.2 mg weekly -6.41%, -8.36%, -11.29% and -12.45% vs placebo +1.67%; placebo-adjusted -8.09% to -14.13%, all p<0.0001 (CT.gov posted results). NCT06712836 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Berobenatide's landscape · Semaglutide (DWRX5003)'s landscape